Form 4: Terns Pharma CMO Sells Shares for Tax Obligations

Terns Pharmaceuticals' Chief Medical Officer, Emil Kuriakose, sold 944 shares of common stock to cover tax liabilities from a restricted stock unit vesting.

Summary

• Emil Kuriakose, Chief Medical Officer of Terns Pharmaceuticals, Inc. (TERN), reported a sale of common stock.
• The transaction involved the disposition of 944 shares of common stock on October 1, 2025.
• The shares were sold at a weighted average price of $7.8464 per share, with prices ranging from $7.74 to $7.91.
• The sale was explicitly stated to satisfy taxes associated with the vesting of a previously granted restricted stock unit award and does not represent a discretionary trade.
• Following this transaction, Emil Kuriakose beneficially owns 51,520 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary sale of shares to cover tax obligations from RSU vesting. This type of transaction is neutral in sentiment as it does not indicate management's view on the company's future prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction, common across all industries, where executives sell shares to cover tax liabilities arising from the vesting of equity awards. It typically does not reflect a change in the company's fundamental outlook or management's confidence.

Comparison to Industry Standards

• This transaction is a standard practice for executives receiving equity compensation, aligning with common industry practices for managing tax obligations upon RSU vesting.
• It is not comparable to industry performance benchmarks or competitive results, as it pertains to individual compensation management rather than company operational or financial performance.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary sale for tax purposes and does not signal a change in management's confidence or company fundamentals.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by a Chief Medical Officer to cover tax liabilities from RSU vesting. Such transactions are common and typically pre-scheduled under Rule 10b5-1 plans. They do not provide new fundamental information about the company's operational performance, strategic direction, or management's outlook that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, as this filing alone does not alter the investment thesis for Terns Pharmaceuticals.

Keywords

Terns Pharmaceuticals, TERN, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Obligation, Emil Kuriakose, Chief Medical Officer, 10b5-1 Plan